First Heartland Consultants’s Sarepta Therapeutics SRPT Stock Holding History

First Heartland Consultants’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-6,520	Closed	-$252K	–	301
2015 Q4	$252K	Hold	6,520	–	–	0.1%	220
2015 Q3	$209K	Buy	+6,520	New	+$221K	0.09%	228
2014 Q3	–	Sell	-6,800	Closed	-$203K	–	269
2014 Q2	$203K	Buy	+6,800	New	+$215K	0.09%	231

Other funds holding SRPT

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

First Heartland Consultants's SRPT Position: Q1 2016 in Review

First Heartland Consultants sold out of Sarepta Therapeutics (SRPT) in Q1 2016, closing a stake of 6,520 shares — an estimated $252K sold.

First Heartland Consultants first reported a position in SRPT in Q2 2014 and held it in 3 quarters. The position peaked at $252K in Q4 2015. 132 funds tracked by Wall St. Rank hold SRPT as of Q1 2016.

First Heartland Consultants reported no remaining Sarepta Therapeutics position as of Q1 2016 after selling out during the quarter.
First Heartland Consultants sold 6,520 Sarepta Therapeutics shares in Q1 2016, an estimated $252K.
First Heartland Consultants first reported a position in Sarepta Therapeutics in Q2 2014 and held it in 3 quarters.
First Heartland Consultants's Sarepta Therapeutics position peaked at $252K in Q4 2015.
132 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2016.

Based on First Heartland Consultants's 13F filing for Q1 2016, filed 10 May 2016.